Shares of Cellular Biomedicine (NASDAQ:CBMG) have been given an average broker rating score of 2.00 (Buy) from the two analysts that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating and one has issued a strong buy rating on the company.
Analysts have set a one year consensus target price of $32.00 for the company and are expecting that the company will post ($0.47) EPS for the current quarter, according to Zacks. Zacks has also assigned Cellular Biomedicine an industry rank of 173 out of 265 based on the ratings given to its competitors.
Several research analysts recently commented on the company. BidaskClub raised Cellular Biomedicine from a “hold” rating to a “buy” rating in a research report on Wednesday, January 10th. Maxim Group cut Cellular Biomedicine from a “buy” rating to a “hold” rating in a research report on Thursday, February 1st. B. Riley reaffirmed a “buy” rating on shares of Cellular Biomedicine in a research report on Friday, March 16th. Finally, ValuEngine raised Cellular Biomedicine from a “sell” rating to a “hold” rating in a research report on Wednesday, April 4th.
Cellular Biomedicine (NASDAQ:CBMG) last announced its quarterly earnings data on Tuesday, March 6th. The biotechnology company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.08). The company had revenue of $0.07 million during the quarter. Cellular Biomedicine had a negative return on equity of 45.60% and a negative net margin of 7,564.10%. sell-side analysts expect that Cellular Biomedicine will post -1.94 EPS for the current year.
In related news, Director Wen Tao Liu sold 10,400 shares of the firm’s stock in a transaction on Tuesday, April 10th. The stock was sold at an average price of $20.10, for a total value of $209,040.00. Following the completion of the transaction, the director now directly owns 223,476 shares of the company’s stock, valued at $4,491,867.60. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 8.30% of the stock is owned by company insiders.
TRADEMARK VIOLATION WARNING: This piece was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://www.chaffeybreeze.com/2018/04/17/zacks-cellular-biomedicine-cbmg-receives-consensus-rating-of-buy-from-brokerages.html.
About Cellular Biomedicine
Cellular Biomedicine Group Inc, a biopharmaceutical company, develops treatments for cancerous and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat serious diseases, such as cancer, orthopedic, and various inflammatory diseases, as well as metabolic diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cellular Biomedicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine and related companies with MarketBeat.com's FREE daily email newsletter.